$3.86 Million in Sales Expected for Orchard Therapeutics plc (NASDAQ:ORTX) This Quarter

Equities research analysts predict that Orchard Therapeutics plc (NASDAQ:ORTXGet Rating) will announce sales of $3.86 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Orchard Therapeutics’ earnings. The highest sales estimate is $6.17 million and the lowest is $2.60 million. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Orchard Therapeutics will report full-year sales of $17.44 million for the current financial year, with estimates ranging from $13.30 million to $22.73 million. For the next fiscal year, analysts anticipate that the company will post sales of $23.92 million, with estimates ranging from $7.30 million to $34.90 million. Zacks’ sales averages are an average based on a survey of analysts that cover Orchard Therapeutics.

Orchard Therapeutics (NASDAQ:ORTXGet Rating) last released its quarterly earnings data on Wednesday, March 30th. The company reported ($0.29) earnings per share for the quarter, meeting the consensus estimate of ($0.29). The company had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.65 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Orchard Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 2nd. Sumitomo Mitsui Financial Group restated a “neutral” rating on shares of Orchard Therapeutics in a research report on Friday, April 1st. Stifel Nicolaus decreased their price target on Orchard Therapeutics from $12.00 to $5.00 in a research report on Thursday, March 31st. Barclays decreased their price target on Orchard Therapeutics from $6.00 to $4.00 in a research report on Friday, May 13th. Finally, Cowen lowered Orchard Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 31st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.00.

ORTX stock opened at $0.46 on Thursday. Orchard Therapeutics has a 1-year low of $0.41 and a 1-year high of $5.54. The firm has a market cap of $57.92 million, a P/E ratio of -0.38 and a beta of 1.20. The business’s 50 day moving average is $0.63 and its 200-day moving average is $0.99. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.17.

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in Orchard Therapeutics in the 3rd quarter valued at $29,000. Cubist Systematic Strategies LLC bought a new position in Orchard Therapeutics in the 3rd quarter valued at $40,000. Forefront Analytics LLC boosted its position in Orchard Therapeutics by 89.7% in the 1st quarter. Forefront Analytics LLC now owns 99,741 shares of the company’s stock valued at $72,000 after buying an additional 47,175 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Orchard Therapeutics by 65.2% in the 3rd quarter. Squarepoint Ops LLC now owns 33,030 shares of the company’s stock valued at $76,000 after purchasing an additional 13,032 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Orchard Therapeutics by 134.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 73,332 shares of the company’s stock valued at $97,000 after purchasing an additional 41,997 shares during the period. Hedge funds and other institutional investors own 56.47% of the company’s stock.

About Orchard Therapeutics (Get Rating)

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.

Featured Articles

Get a free copy of the Zacks research report on Orchard Therapeutics (ORTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orchard Therapeutics (NASDAQ:ORTX)

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.